Activating signal cointegrator 2 required for liver lipid metabolism mediated by liver X receptors in mice by Kim, SW et al.
MOLECULAR AND CELLULAR BIOLOGY, May 2003, p. 3583–3592 Vol. 23, No. 10
0270-7306/03/$08.000 DOI: 10.1128/MCB.23.10.3583–3592.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Activating Signal Cointegrator 2 Required for Liver Lipid Metabolism
Mediated by Liver X Receptors in Mice
Seung-Whan Kim,1 Keunhee Park,1 Eunyee Kwak,1 Eunho Choi,1 Seunghee Lee,1 Jungyeob Ham,2
Heonjoong Kang,2 Jong Man Kim,3 Seung Yong Hwang,3 Young-Yun Kong,1 Keesook Lee,4
and Jae Woon Lee1*
Department of Life Science, Pohang University of Science and Technology, Pohang 790-784,1 School of Earth and
Environmental Sciences, Seoul National University, Seoul 151-742,2 Department of Biochemistry and Molecular
Biology and GenoCheck Co. Ltd., Hanyang University, Ansan 425-791,3 and
Hormone Research Center, Chonnam National University, Kwangju 500-757,4 Korea
Received 24 October 2002/Returned for modification 12 December 2002/Accepted 14 February 2003
Activating signal cointegrator 2 (ASC-2), a cancer-amplified transcriptional coactivator of nuclear receptors
and many other transcription factors, contains two LXXLL-type nuclear receptor interaction domains. Inter-
estingly, the second LXXLL motif is highly specific to the liver X receptors (LXRs). In cotransfection, DN2, an
ASC-2 fragment encompassing this motif, exerts a potent dominant-negative effect on transactivation by LXRs,
which is rescued by ectopic coexpression of the full-length ASC-2 but not by other LXXLL-type coactivators,
such as SRC-1 and TRAP220. In contrast, DN2/m, in which the LXXLL motif is mutated to LXXAA to abolish
the interactions with LXRs, is without any effect. Accordingly, expression of DN2, but not DN2/m, in transgenic
mice results in phenotypes that are highly homologous to those previously observed with LXR/ mice,
including a rapid accumulation of large amounts of cholesterol and down-regulation of the known lipid-
metabolizing target genes of LXR in the liver upon being fed a high-cholesterol diet. These results identify
ASC-2 as a physiologically important transcriptional coactivator of LXRs and demonstrate its pivotal role in
the liver lipid metabolism.
The nuclear receptor superfamily is a group of proteins that
regulate, in a ligand-dependent manner, transcriptional initia-
tion of target genes by binding to specific DNA sequences
called hormone response elements (31). Genetic studies have
indicated that transcription coactivators without specific DNA-
binding activity are essential for transcriptional activation,
which led to the identification of many proteins interacting
with the C-terminal ligand-dependent transactivation domain
of nuclear receptors (23, 33, 40). These coactivators, including
the p160 family, CBP/p300, p/CAF, TRAP/DRIP, and many
others, bridge transcription factors and the basal transcription
apparatus and/or remodel the chromatin structures.
Activating signal cointegrator 2 (ASC-2), also called AIB3,
TRBP, RAP250, NRC, and PRIP, is a recently isolated tran-
scriptional coactivator molecule which is gene amplified and
overexpressed in human cancers and stimulates transactivation
by nuclear receptors, AP-1, NF-B, SRF, and numerous other
transcription factors (5, 19, 24–26, 30, 46, 58). In particular,
single-cell microinjection results with ASC-2 antibody have
demonstrated that endogenous ASC-2 is required for transac-
tivation by nuclear receptors and AP-1 (24, 25). More recently,
ASC-2 was found to exist in a 2-MDa steady-state complex
which also contains histone H3-lysine 4-specific methyltrans-
ferase enzymes (12). Interestingly, ASC-2 contains two nuclear
receptor interaction domains (26), both of which are depen-
dent on the integrity of their core LXXLL sequences (14, 48).
The C-terminal LXXLL motif specifically interacts with liver X
receptor  (LXR) and LXR, whereas the N-terminal motif
binds a broad range of nuclear receptors (26).
LXR (NR1H3) and LXR (NR1H2) are known to control
cholesterol and fatty acid metabolism. LXR is expressed
mainly in the liver, whereas LXR is ubiquitously expressed
(47, 53). The physiological ligands for LXRs are oxysterols,
and the most potent ones are 22(R)-hydroxycholesterol, 24(S)-
hydroxycholesterol, and 24(S),25-epoxycholesterol (27). Acti-
vation of LXR in macrophages results in increased expression
of genes encoding the ATP-binding cassette (ABC) cholesterol
transporters ABCA1 (9, 37, 42, 50) and ABCG1 (21, 51) and
apolipoprotein E (21) that are involved with cholesterol efflux
from macrophages toward high-density lipoproteins. In the
liver, LXR is involved in transcriptional control of Cyp7A1,
encoding a critical enzyme in the conversion of cholesterol into
bile acids (27, 35), as well as ABCG5/ABCG8 (3, 38), encoding
ABC transporters implicated in biliary cholesterol excretion.
Induction of intestinal ABCA1, ABCG5, and ABCG8 expres-
sion upon LXR activation accelerates fecal cholesterol dis-
posal by reducing the efficiency of cholesterol absorption (37).
LXR has also been reported to control genes that encode
proteins involved in de novo lipogenesis. In particular, induced
transcription has been reported for the gene encoding
SREBP-1c (39, 41, 56), a transcription factor that regulates the
expression of various lipogenic genes, including those encoding
acetyl-coenzyme A (CoA) carboxylase and fatty acid synthase
(15). In addition, LXR is known to directly influence the tran-
scription of genes encoding fatty acid synthase (17), lipopro-
tein lipase (57), cholesterol ester transfer protein (29), and
stearoyl-CoA desaturase 1 (28).
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Gene-targeting approaches to elucidate the roles of many
coactivators in mice have often been hampered by early em-
bryonic lethality or functional redundancy. In particular, dele-
tion of the ASC-2 gene also resulted in early embryonic lethal-
ity (20, 59). As an alternative approach, we have recently
expressed a dominant-negative fragment of ASC-2 encompass-
ing the N-terminal LXXLL motif (i.e., DN1) in mice, which
inhibited recruitment of the endogenous ASC-2 to nuclear
receptors. These DN1-transgenic (TG) mice exhibited a pleth-
ora of developmental and phenotypic abnormalities, including
problems with the eye and heart, motor activities, and fat
metabolism in the liver (18). Importantly, these mice were
significantly compromised in the ability to respond to exoge-
nous ligands, including retinoids (reference 18 and our unpub-
lished results).
In this study, we took a similar approach and established
transgenic mice expressing DN2, a dominant-negative frag-
ment of ASC-2 that encompasses the LXR-specific second
LXXLL motif and potently represses transactivation by LXRs
in cotransfections. Accordingly, these DN2-TG mice exhibited
phenotypes that are highly homologous to those previously
observed with LXR/ mice (35). Together with the DN1-
TG mouse results (18), these results strongly suggest that
ASC-2 is a physiologically pivotal transcriptional coactivator
protein of LXRs and other nuclear receptors in vivo.
MATERIALS AND METHODS
Generation of transgenic mice. For construction of transgenic mice, hemag-
glutinin (HA)-tagged DN2 and DN2/m (in which the LXXLL motif is mutated
to LXXAA to abolish the interactions with LXRs) were cloned into a mamma-
lian expression vector, pCAGGS (34), containing the chicken -actin promoter
linked to a human cytomegalovirus (CMV) immediate-early enhancer. These
plasmids were microinjected into fertilized mouse eggs of the C57BL/6 strain.
The genotype was determined by PCR and Southern analysis of genomic DNA
from tail biopsies. The primers used for genotyping were 5-CCGCTCGAGAT
GGCCTCCTACCCTTAT-3 and 5-GAAGATCTTCATGTAAGCCCAGGG
GG-3. Three and two lines of independent transgenic founders expressing DN2
and DN2/m, respectively, in various tissues were obtained, as demonstrated for
transgenic expression by Western blot analysis or immunohistochemistry with
anti-HA (HA) antibody.
Transfections. HeLa and CV-1 cells were grown in 24-well plates with medium
supplemented with 10% fetal calf serum for 24 h and transfected with 100 ng of
the lacZ expression vector pRSV--gal and 100 ng of LXRE-LUC reporter gene,
along with appropriate amounts of mammalian expression vectors for LXR,
ASC-2, DN2, DN2/m, SRC-1, and TRAP220. The total amounts of expression
vectors were kept constant by adding pcDNA3. Transfections and luciferase
assays were done as described previously (24), and the results were normalized
to lacZ expression. Similar results were obtained in more than two similar
experiments.
GST pull-down and yeast two-hybrid assays. Glutathione S-transferase (GST)
fusions or GST alone was expressed in Escherichia coli, bound to glutathione-
Sepharose 4B beads (Pharmacia, Piscataway, N.J.) in binding buffer (25 mM
HEPES [pH 7.8], 0.2 mM EDTA, 20% glycerol, 100 mM KCl, and 0.1% NP-40),
and incubated with labeled proteins expressed by in vitro translation by using the
TNT-coupled transcription-translation system (Promega, Madison, Wis.), with
conditions as described by the manufacturer. Specifically bound proteins were
eluted from beads with 40 mM reduced glutathione in 50 mM Tris (pH 8.0) and
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and au-
toradiography as described previously (24). Yeast two-hybrid assays were done as
described previously (24). A yeast expression vector encoding LexA fused to the
full-length LXR was obtained from Young-Chul Lee at Chonnam National
University. Yeast expression vectors encoding LexA-LXR and B42-DN2 were
as previously described (26).
Chromatin immunoprecipitation. 293T cells transfected with DN2 or DN2/m
expression vector were treated with 5 M T0901317 for 40 min. Soluble chro-
matin from these cells was prepared and immunoprecipitated with appropriate
antibodies, as recently described (44). The final DNA extractions were amplified
using pairs of primers that encompass the LXR-responsive element of the
SREBP-1c promoter region and generate a 320-bp PCR product. The primers
used were 5-AAGGGCCAGGAGTGGGTAAAC-3 and 5-CGCGCCGCGC
CCCATTAGG-3.
Histological examination and immunohistochemistry. Organs were excised,
frozen, sectioned in 10-m-thick slices, and stained with hematoxylin and eosin
and oil red O, as described previously (43). The organs examined were the eyes,
liver, kidney, heart, lung, spleen, stomach, brain, pituitary gland, gall bladder,
and adrenal gland from mouse embryos and postnatal animals.
Cholesterol and triglyceride measurement. Plasma from euthanized mice was
prepared using standard centrifugation techniques and enzymatically analyzed
for cholesterol and triglyceride as previously described (16). Hepatic lipids were
extracted from 0.2 g of liver and analyzed for triglyceride and cholesterol as
described previously (4, 55).
DNA microarrays. The mouse cDNA microarrays consisted of 8,000 cDNAs,
including mouse clones from Incyte Genomics, Inc. (Palo Alto, Calif.), as well as
housekeeping genes; tissue-specific genes; positive, negative, ratio, and sensitivity
controls; and other controls. The PCR-amplified cDNAs were printed on CMT-
GAPS II silane slide glass (Corning) and processed according to the manufac-
turer’s protocol. Total RNA extracted from the treated and untreated livers of
wild-type and DN2-TG mice was reverse transcribed to fluorescence-labeled
cDNA probes using SuperScript II reverse transcriptase (Gibco BRL, Life Tech-
nologies, Grand Island, N.Y.) and Cy3- or Cy5-labeled dCTP (NEN Life Science
Products Inc). The Cy3- and Cy5-labeled cDNAs were placed on the slide and
hybridized in a hybridization chamber. The hybridized slides were scanned with
the Axon Instruments (Union City, Calif.) GenePix 4000B. Finally, the scanned
images were analyzed with GenePix Pro 3.0 (Axon) and GeneSpring (Silicon
Genetics, Redwood City, Calif.). The signals of GAPDH and -actin housekeep-
ing genes were used for normalization.
RESULTS
DN2 as a specific dominant-negative mutant of LXR. The
second LXXLL motif of ASC-2 has been characterized as a
specific interaction interface with LXRs (26). In an effort to
identify important residues for this specificity, we constructed
a series of chimeric proteins that incorporate various residues
of the second LXXLL motif into ASC2-2c. Radiolabeled
ASC2-2c itself, which consists of the ASC-2 residues 849 to
1057, containing the first LXXLL motif, bound to GST protein
fused to TR but not LXR in a ligand-dependent manner,
was previously described (26) (Fig. 1A). However, introduction
of as little as 10 residues surrounding the second LXXLL motif
was sufficient to change the binding specificity of the resulting
chimeric protein (i.e., ASC2-2c/m7) to bind GST-LXR (Fig.
1A). Consistent with these results, specific residues within this
10-amino-acid region in ASC2-2c/m7 were identified as the
residues most critical for LXR binding, as demonstrated by our
recent random mutagenic analysis of an 100-amino-acid re-
gion surrounding the second LXXLL motif of ASC-2 (our
unpublished results). It is interesting that the sequences of this
second LXXLL motif were unique, and we could not find any
similar motif in different protein databases. Similarly, DN2,
previously called ASC2-4LR (26), which encodes the ASC-2
residues 1431 to 1511 and contains the second LXXLL motif,
interacted with LXR (Fig. 1B).
It was previously reported that DN2 represses transactiva-
tion by LXR (26). Similarly, DN2 was a potent dominant-
negative mutant of LXR in cotransfections in both the ab-
sence and presence of its ligand, 22(R)-hydroxycholesterol
(Fig. 2A). In contrast, DN2/m, in which the LXXLL motif was
mutated to LXXAA, had no effect. It should be noted that
DN2 is inert with transactivation by other nuclear receptors
that do not bind this second LXXLL motif, including thyroid
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hormone receptors and retinoic acid receptor  (data not
shown). Importantly, the inhibition was rescued by coex-
pressed ASC-2 but not by two well-characterized LXXLL-type
coactivators, SRC-1 and TRAP220 (Fig. 2B). These results
were further confirmed in chromatin immunoprecipitation as-
says with 293T cells cotransfected with vectors encoding DN2
and DN2/m. As shown in Fig. 2C, the LXRE region of
SREBP-1c was occupied by ASC-2, TRAP220, and GRIP1.
DN2 specifically inhibited the recruitment of ASC-2 without
interfering with the recruitment of TRAP220 and GRIP1. In
contrast, DN2/m had no significant effect on the recruitment of
any of these factors. Consistent with the reported relatively
higher basal activities of LXRs under these conditions (47, 53),
similar results were also obtained in the absence of exogenous
ligand (data not shown). The exact mechanism responsible for
this specificity is not clear. Nonetheless, these results demon-
strate that DN2 can serve as an excellent tool to study the
LXR-specific function of ASC-2, i.e., DN2 specifically inhibits
LXR transactivation by blocking the recruitment of endoge-
nous ASC-2 to LXRs bound to the target promoters.
Construction of DN2-TG mice and their phenotypic analy-
sis. Based on the results presented above, we hypothesized that
any phenotype in DN2-expressing transgenic mice not ob-
served with DN2/m-expressing mice should reflect the in vivo
function of ASC-2 specific to LXRs. Thus, we exploited the
ubiquitously active -actin promoter to obtain three indepen-
dent transgenic founder mouse lines (designated DN2-TG)
FIG. 1. The second LXXLL motif specifically binds to LXR and
LXR. (A) A series of chimeric proteins containing amino acids of the
second LXXLL motif region within the context of ASC2-2c (i.e., the
ASC-2 residues 849 to 1057) were constructed using two-step PCR
procedures and synthesized as labeled proteins expressed by in vitro
translation using the TNT-coupled transcription-translation system,
with conditions as described by the manufacturer. These proteins were
incubated with GST fusion to TR and LXR in the absence and
presence of either 0.1 M T3 or 10 M T0901317, as previously
reported (20). Twenty percent of the total reaction mixture was loaded
as input. The ASC-2 residues 875 to 907 (shaded) and 1479 to 1511
(open), containing the first and second LXXLL motif, respectively, are
shown. (B) The indicated B42 and LexA plasmids were transformed
into a yeast strain containing an appropriate lacZ reporter gene, as
described previously (24). The shaded and solid bars indicate the
absence and presence of 1 M of 22(R)-hydroxycholesterol, respec-
tively. Better ligand responsiveness was observed with higher doses of
22(R)-hydroxycholesterol (data not shown). , B42 alone.
FIG. 2. DN2 as a specific dominant-negative repressor of LXR
transactivation. (A and B) An oxysterol-responsive LXRE-LUC re-
porter construct was cotransfected into HeLa cells, along with lacZ
expression vector (100 ng) and expression vectors for ASC-2, DN2
(i.e., the ASC-2 residues 1431 to 1511), DN2/m, TRAP220, and SRC-1,
as indicated. The solid and shaded bars indicate the absence and
presence of 10 M 22(R)-hydroxycholesterol, respectively. Normalized
luciferase expressions from triplicate samples were calculated relative
to the lacZ expression. Similar results were obtained with CV-1 cells
(data not shown). The error bars indicate standard deviations.
(C) ASC-2 recruitment to the LXRE region of SREBP-1c. 293T cells
were cotransfected with expression vectors for DN2 (50 and 100 ng)
and DN2/m (50 and 100 ng) in the presence of 5 M T0901317, as
indicated. Chromatin from these cells was isolated and immunopre-
cipitated (IP) by the indicated antibodies. The endogenous SREBP-
1c-LXRE region present in the immunoprecipitated samples was am-
plified by PCR, and the input PCR (10%) is shown for loading
controls. Similar results were also obtained in the absence of ligand
(data not shown).
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that express HA-tagged DN2 in various tissues examined, as
well as two HA-DN2/m-expressing founder lines (designated
DN2/m-TG). Interestingly, DN2-TG mice did not show any
apparent phenotype, in contrast to a variety of pathological
anomalies recently reported with DN1-TG mice (18) (Table 1).
However, it should be noted that this lack of phenotype was
consistent with the specificity of DN2 to LXRs and the absence
of any apparent developmental function ascribed to LXRs (47,
53).
Impaired cholesterol metabolism with DN2-TG mice on a
high-cholesterol diet. As the expected lack of apparent phe-
notypes was confirmed, we next explored the status of the
known signaling pathways of LXRs in DN2-TG mice. Among
the three major physiological targets of LXRs with regard to
cholesterol and fatty acid metabolism (i.e., the liver, macro-
phages, and the intestine), we decided to focus on the detailed
phenotypic analysis of the liver in this report. The results with
macrophages and intestines will be described elsewhere. First,
the expressions of DN2 and DN2/m in the livers of DN2-TG
and DN2/m-TG mice, respectively, were confirmed by indirect
immunofluorescence assays (Fig. 3A and data not shown). It
should be noted that mice lacking LXR were previously
shown to lose the ability to respond normally to dietary cho-
lesterol and are unable to tolerate any amount of cholesterol in
excess of that which they synthesize de novo (29). Thus, we
tested the effect of a diet rich in cholesterol (chow supple-
mented with 2% cholesterol). Remarkably, there were dra-
matic morphological, histological, and chemical changes in the
livers of DN2-TG mice fed the same diet. Within 7 days of
beginning the 2% cholesterol diet, and chronically worsening
over a 90-day period, there were prominent color and size
changes in the DN2-TG livers (Fig. 3B). Consistent with the
known ability of wild-type animals to adapt quickly to choles-
terol-rich diets, the livers of wild-type animals maintained rel-
atively normal appearance and function. As expected, at least
two independent DN2/m-TG lines were phenotypically indis-
tinguishable from wild-type mice, allowing us to use both DN2/
m-TG and wild-type mice as controls. Histological examination
of the DN2-TG mouse livers revealed the presence of a time-
dependent increase in the number and size of intracellular
vacuoles, characteristic of lipid deposits (Fig. 3C, left). Oil red
O staining of these liver sections verified the deposition of lipid
(Fig. 3C, right). Plasma cholesterol levels rose significantly
(	200%) in DN2-TG mice over the course of the 90-day high-
cholesterol diet, while wild-type mice characteristically showed
no change (Fig. 3D). Chemical analysis showed that the accu-
mulated lipid within the livers of DN2-TG mice is in the form
of cholesterol (Fig. 3E). In wild-type animals, there were rel-
atively fewer significant changes in liver histology, size, and
hepatic cholesterol levels (Fig. 3B, C, and E and data not
shown). Overall, these results support the importance of
ASC-2 as a specific coactivator of LXRs in vivo.
Impaired de novo lipid synthesis in the livers of DN2-TG
mice. LXR has been reported to control genes that encode
proteins involved in de novo lipogenesis. These include
SREBP-1c (15, 39, 41, 56), fatty acid synthase (17), lipoprotein
lipase (57), cholesterol ester transfer protein (29), and
stearoyl-CoA desaturase-1 (28). Furthermore, it was recently
shown that induction of these lipogenic genes with the syn-
thetic LXR ligand T0901317 in mice is associated with an
increased secretion of very low density lipoprotein-triglyceride
and massive hepatic steatosis along the entire liver lobule (13).
Consistent with these results, DN2-TG mice fed T0901317
showed reduced amounts of lipid accumulation in the liver
relative to wild-type mice (Fig. 4A). Similarly, examination of
hepatic triglyceride levels revealed a significant T0901317-de-
pendent increase with wild-type mice but not with DN2-TG
mice (Fig. 4B). These results further strengthen the impor-
tance of ASC-2 as a specific coactivator of LXRs in vivo.
A subset of LXR target genes altered in expression with
DN2-TG. It is important to note that ASC-2 also has a multi-
tude of other target nuclear receptors and transcription factors
(5, 19, 24–26, 30, 46, 58). Thus, our results, which demon-
strated the validity of DN2-TG mice as a novel animal model
system to study the LXR-specific function of ASC-2 in vivo,
FIG. 3. Morphology and histology of livers from DN2-TG (TG)
and wild-type (WT) mice on high-cholesterol diets. (A) Expression of
DN2 was assessed with indirect immunofluorescence with HA anti-
body. TG #4 indicates the DN2-TG line no. 4 (Table 1). (B) Gross
morphology of livers from male DN2-TG and wild-type mice fed chow
supplemented with 2% cholesterol (HCD, high-cholesterol diet) for 90
days. ND, normal chow diet. The development of fatty livers in the
DN2-TG mice is evident after 7 days on the high-cholesterol diet.
(C) Sections from livers shown in panel B were prepared for histology
and stained with oil red O, as indicated. The unstained vacuoles visible
in the hematoxylin and eosin (H & E)-stained sections of the livers
from DN2-TG mice on the high-cholesterol diet stain positive (red) for
lipids with oil red O. (D and E) Measurements of plasma and hepatic
cholesterol quantitated enzymatically from extracts of the livers shown
in panel B. All values are expressed as means plus standard errors of
the mean; n 
 5.
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attest to the beauty of our transgenic approach over a general
deletion of the ASC-2 gene (20, 59). To further confirm the
LXR specificity of DN2-TG mice, as well as to identify addi-
tional hepatic target genes of the LXR ligand T0901317 in
mice, we analyzed the T0901317-dependent gene expression
profile of the DN2-TG liver by employing DNA microarray
experiments. The microarrays we analyzed consisted of 8,000
mouse cDNAs, as well as various control genes. For these
experiments, three wild-type mice were treated with vehicle
alone, while six wild-type and three DN2-TG mice were orally
fed 50 mg of T0901317/kg of body weight for 6 days, after
which their livers were excised to isolate total RNA. Samples
from these animals were randomly paired to generate three
sets of vehicle-treated wild-type mice versus T0901317-treated
wild-type mice, as well as three sets of wild-type mice versus
DN2-TG mice, both treated with T0901317. The first three sets
were designed to isolate all the T0901317-responsive genes,
while the second three sets were designed to identify genes
responsive to both DN2 and T0901317. First, the data were
remarkably consistent with each other within each set. In par-
ticular, the results with a group of genes most responsive to
T0901317 and DN2 were highly reproducible both in rank
order and fold induction or repression (Tables 2, 3, and 4).
Second, it was interesting that only a subset of genes either up-
or down-regulated by T0901317 in wild-type mice were af-
fected by the presence of DN2 (Tables 2 and 3). For instance,
among the 38 genes most up-regulated by T0901317, only 12
genes (i.e., 32%) were significantly down-regulated in
DN2-TG mice relative to wild-type mice (Table 2). Similarly,
among the 38 genes most down-regulated by T0901317, only 7
genes (i.e., 18%) were up-regulated in DN2-TG mice (Table
3). These results strongly suggest that the presence of LXR-
responsive elements, either direct or indirect, is not sufficient
to confer ASC-2 responsiveness. This notion is consistent with
the general requirement of highly regulated mammalian genes
for multiple cis elements and the resultant assembly of a high-
er-order transcription enhancer complex (i.e., an enhanceo-
some) consisting of multiple coregulatory proteins and tran-
scription factors occupying these cis elements (reviewed in
reference 32). Table 4 lists the most up- and down-regulated
genes in T0901317-treated DN2-TG mice relative to
T0901317-treated wild-type mice. Importantly, 55 and 60% of
these genes were down- and up-regulated, respectively, by
T0901317 in wild-type mice (Table 4). These results reinforce
the notion that the major group of genes affected in T0901317-
treated DN2-TG mice is indeed genuine LXR-target genes. It
FIG. 4. Impaired lipogenesis in DN2-TG mice. (A) Liver sections
from wild-type (WT) and DN2-TG (TG) mice treated orally with
vehicle or 50 mg of T0901317/kg for 6 days were prepared for histology
and stained with oil red O, as indicated. #18, DN2-TG line no. 18.
(B) Measurements of hepatic triglyceride quantitated enzymatically
from extracts of the livers shown in panel A. All values are expressed
as means plus standard errors of the mean; n 
 5.
TABLE 1. Phenotypes exhibited by DN1 and DN2-TG
Abnormality
Presence in transgenic line no.a
DN1 DN2
54 71 84 87 104 4 18 32
Eye
Embryonic eye
Microphthalmia    NA    
Retinal dysplasia    NA    
Sclera locally thinner or
missing
   NA    
Retrolenticular membrane    NA    
PHPVb    NA    
Cataracts    NA    
Adult eye
Posterior lenticonus    NA    
Cataracts        
Microphthalmia        
Retinal dysplasia    NA    
Sclera locally thinner or
missing
   NA    
Retrolenticular membrane    NA    
PHPV    NA    
Heart
Embryonic heart
Ventricular septal defects ND ND  ND ND ND ND ND
Adult heart
Atrial thrombosis        
Hypertrophy        
Conduction defects    ND    
Respiratory tract ND ND ND
Lung hypoplasia     
Lung congestion     
Lung inflammation     
Liver
Fatty liver on normal diet        
Fatty liver with high-cholesterol
diet
ND ND ND ND ND   
Thymic atrophy (agenesis)        
Spleen atrophy        
Gall bladder hydrops        
Kidney hypoplasia        
Pituitary gland redness      ND ND ND
Adrenal gland redness        
Motor defects  ND  ND ND ND ND ND
a , present; , absent; NA, not applicable; ND, not determined.
b PHPV, persistent hyperproliferation of primary vitreous.
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is also interesting that there is not a strict correlation between
the rank order and the potency (i.e., fold induction or repres-
sion). For instance, AA473153 and AA213017 are repressed to
0.78- and 0.48-fold, respectively, by T0901317 in wild-type
mice, i.e., AA213017 is more responsive to T0901317 (Table
4). However, AA473153 is up-regulated 5.00-fold in ligand-
treated DN2-TG mice over ligand-treated wild-type mice,
whereas AA213017 is up-regulated only 2.20-fold. Thus, a gene
less responsive to ligand (i.e., AA473153) proves to be more
responsive to DN2. Overall, these results validate the utility of
our DN2-TG mice as a model system to study the LXR-specific
function of ASC-2 in vivo.
These cDNA microarray results allowed us to directly iden-
tify a series of novel hepatic genes targeted by ASC-2 and
LXRs. For instance, genes encoding peroxisome proliferator-
activated receptor  (PPAR) and insig-2 (54) were found to
be positively regulated by T0901317 in an ASC-2-dependent
manner (Tables 2 and 3). These results were further confirmed
by reverse transcription (RT)-PCR (Fig. 5A). Expression of
insig-2 was also induced by T0901317 in the murine hepatoma
cell line hepa-1c1c7 (Fig. 5B). Like the previously described
insig-1, insig-2 binds to SREBP cleavage-activating protein in a
sterol-regulated fashion and prevents the proteolytic process-
ing of SREBPs by Golgi enzymes, thereby blocking cholester-
ol-lipid synthesis (54). Both PPAR and insig-2 may play im-
portant roles in the liver lipid metabolism mediated by LXRs.
A novel IB kinase complex containing PMA-inducible IKKε,
TABLE 2. Genes up-regulated by T0901317
Gene Name
Fold changea
WT/
WT
DN2-TG/
WT
AA109684 P450, 4A10 7.87 NA
AA197454 EST 6.05 0.32
AI893661 P450, 4A14 6.03 NA
AA200989 EST 5.46 0.38
AA288170 EST 4.20 3.68
AA270506 EST 4.18 0.98
AI464827 EST 3.98 0.36
AA444946 insig-2 3.89 0.36
AA009268 Myelocytomatosis
oncogene
3.83 0.95
W98251 EST 3.79 0.36
AA239254 EST 3.47 1.81
AA175346 EST 3.46 0.83
AA458178 CD36 3.42 0.99
AA466026 EST 3.40 0.63
AA067967 EST 3.21 1.06
AA268120 P450, 3A11 2.96 0.94
W64388 Myeloid response
gene 118
2.94 1.25
AA238875 Aledehyde
dehydrogenase 4
2.77 1.15
AA122542 EST 2.74 1.34
AA122814 Aledehyde
dehydrogenase 1
2.66 1.04
AA261287 Peroxisomal acyl-CoA
oxidase
2.59 0.84
AA267605 PPAR 2.57 0.49
AA467249 EST 2.53 1.28
W89594 EST 2.48 0.81
AA271522 EST 2.46 1.40
AA108340 C3f gene 2.45 1.06
AA276752 EST 2.42 0.96
A1587794 EST 2.40 1.01
AA087206 EST 2.36 1.22
AA106263 EST 2.28 1.24
AA271043 EST 2.28 0.94
AA097860 CDC-like kinase 2 2.21 1.02
AA259400 EST 2.20 0.71
AA275203 EST 2.17 0.96
AA097194 EST 2.15 0.97
AA245078 Fatty acid binding
protein
2.09 0.87
AA458273 EST 2.08 1.12
W87950 EST 2.06 1.01
a , treated with T0901317; , treated with vehicle; italics, significantly down-
regulated in DN2-TG mice.
TABLE 3. Genes down-regulated by T0901317
Gene Name
Fold changea
WT/
WT
DN2-TG/
WT
AA108438 EST 0.37 0.86
AA239479 EST 0.43 0.69
W66757 EST 0.46 1.16
A1604749 EST 0.47 NA
AA014384 EST 0.47 2.01
AA213017 Monooxygenase 3 0.48 2.20
AA271451 C-reactive protein,
pretexin related
0.49 1.46
AA285921 Major urinary
protein 2
0.50 1.00
AA245847 EST 0.50 1.00
W83009 EST 0.50 1.08
AA238208 EST 0.51 1.00
AA154452 EST 0.51 1.10
AA542013 Fibroblast growth
factor receptor
0.52 0.96
AI385792 Sulfotransferase-
related protein
0.52 0.69
AA218405 1KKε 0.52 1.00
W11846 EST 0.53 1.27
AA239480 EST 0.54 1.13
AA259979 Angiotensinogen 0.54 1.26
AA213062 EST 0.54 1.12
W18484 MEL91 0.55 NA
AA260520 Ets variant gene 6 0.56 1.09
AA476030 EST 0.57 0.80
AA212899 Deiodinase,
iodothyronine,
type
0.57 0.96
AA277314 Angiogenin-3 0.57 1.55
W11759 EST 0.57 NA
AA241936 EST 0.57 0.98
AI893937 Protein tyrosine
phosphatase
0.58 1.00
AA414106 EST 0.58 NA
AA153024 EST 0.58 1.13
AI605748 EST 0.59 0.93
AA266146 EST 0.59 1.01
W47974 EST 0.59 NA
W34018 EST 0.60 NA
AA062129 Inter-trypsin
inhibitor, hc 3
0.60 0.80
AA122791 Histocompatibility
2, Q locus 7
0.60 1.15
W10072 IGF 1 0.60 0.89
AI390830 EST 0.60 0.90
AA174320 EST 0.60 1.77
a , treated with T0901317; , treated with vehicle; italics, significantly up-
regulated in DN2-TG mice.
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distinct from the well-characterized high-molecular-weight IB
kinase complex containing IKK, IKK, and IKK, was re-
cently reported (36). Interestingly, IKKε was identified as a
T0901317-repressible gene from the cDNA microarray exper-
iments, although it was not a direct target gene of ASC-2
(Tables 2 and 3). In the macrophage cell line RAW264.7, IKKε
was indeed repressed by T0901317 (Fig. 5C). However,
T0901317 did not affect expression of IKK, while it signifi-
cantly induced IKK. These results suggest the presence of a
complex cross talk between two distinct signaling pathways
(i.e., LXRs and NF-B). Overall, these results demonstrate the
credibility of our cDNA microarray results. More importantly,
studies of these and other identified genes in the liver lipid
metabolism will provide an important insight into the complex
hepatic signaling pathways mediated by ASC-2 and LXRs in
vivo.
Expression of lipid-metabolizing LXR target genes in
DN2-TG mice. Unfortunately, our cDNA microarray chips did
not include most of the known target genes of LXRs, partic-
ularly ones involved with reverse cholesterol transport and
lipogenesis in the liver. Thus, we employed RT-PCR to directly
assess the expression patterns for some of these genes in the
livers of DN2-TG mice. Interestingly, these experiments re-
vealed that only a subset of the genes examined are impaired
in DN2-TG mice (Fig. 6A), consistent with our cDNA microar-
ray results (Tables 2 through 4). For instance, the LXR target
genes ABCA1, ABCG1, and ABCG8 were less sensitive to the
expression of DN2 in DN2-TG mice fed high-cholesterol diets.
However, high-cholesterol-diet-induced expression of LPL,
ABCG5, FAS, SREBP-1c, and Cyp7A1 genes was significantly
impaired in DN2-TG mice. Similarly, T0901317-induced ex-
pression of LPL, SREBP-1c, and ABCG5 was also impaired in
DN2-TG mice (Fig. 6B). These results, along with our cDNA
microarray results, suggest that ASC-2 likely regulates only a
selective set of the LXR target genes in vivo, further support-
ing the importance of the context of the individual target gene
and cell type in ASC-2 responsiveness (32). Likewise, ASC-2 is
FIG. 5. Confirmation of cDNA microarray results. Total RNA was
prepared using Trizol reagent (Life Technologies), according to the
instructions given by the manufacturer, from wild-type and DN2-TG
mice treated with vehicle alone or 50 mg of T0901317/kg for 6 days
(A), as well as Hepa-1c1c7 (B) and RAW264.7 (C) cells treated with
either vehicle alone or 10 M T0901317 for 16 h, as indicated. Semi-
quantitative RT-PCR was used to determine the relative levels of
mRNA for insig-2, PPAR, IKKε, IKK, IKK, and GAPDH. #4,
DN2-TG mouse line no. 4.
TABLE 4. Genes most up- and down-regulated by T0901317 in
transgenic versus wild-type mice
Gene Name
Fold changea
WT/
,
WT
DN2-TG/
WT
AA473153 EST 0.78 5.00
AA288170 EST 4.20 4.57
AA060979 EST 0.62 4.17
AA020307 VLDL receptor 0.96 3.21
AA244820 EST 0.64 3.06
AA238618 EST 1.04 2.94
AI323180 Cyclin D1 0.90 2.82
AA269533 Cyp2B9 0.87 2.71
AA048915 G nucleotide BP, beta-
2 related
0.86 2.68
AI510113 EST 0.84 2.68
AA125367 Protein tyrosine
phosphtase 16
0.92 2.65
W36002 EST 1.01 2.35
AA144169 EST 0.94 2.24
AA268608 Squalene epoxidase 0.72 2.23
AA276003 Prolactin receptor-
related 1
0.73 2.16
AA388607 EST 1.13 2.01
AA014384 EST 0.57 2.01
AA542160 EST 1.25 1.98
AA213017 Monooxygenase 3 0.48 2.20
AA268587 Serum amyloid P
component
0.78 1.80
AA290107 EST 1.13 2.02
AA153205 EST 0.81 1.77
AA472154 EST 1.03 0.29
W88005 EST 2.00 0.31
AA197454 EST 6.05 0.32
AA097421 Apolipoprotein A-IV 1.98 0.32
AA255171 EST 0.87 0.32
W98251 EST 3.79 0.36
AA444946 insig-2 3.89 0.36
AA108370 GST, pi 2 1.43 0.37
AA008579 ABCG2 1.71 0.38
AA177549 EST 1.12 0.38
AA200989 EST 5.46 0.38
AA466026 EST 4.00 0.39
AA221226 EST 2.69 0.41
AA254921 Esterase 31 0.46 0.42
AA177717 Interleukin 1 receptor,
type 1
1.06 0.43
AI464827 EST 3.98 0.44
AI386390 Translation initiation
factor 2–3
1.95 0.44
AA064236 EST 4.43 0.45
AA145237 EST 0.69 0.45
AI893893 Cytokine-inducible SH2
protein
0.94 0.51
AA245505 Cyokine-inducible SH2
protein 2
1.16 0.53
AI322465 Caseinolytic protease X
(Escherichia coli)
1.56 0.54
AA049246 EST, NEDD4 1.26 0.56
AA175618 EST 1.10 0.57
AA230822 EST 1.05 0.57
a , treated with T0901317; , treated with vehicle; italics, significantly up- or
down-regulated in wild-type mice.
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predicted to regulate only a subset of target genes of other
nuclear receptors.
DISCUSSION
Our results clearly demonstrate that expression of at least a
subset of LXR-target genes is impaired in the livers of
DN2-TG mice, implicating ASC-2 as an essential coactivator
of LXRs in vivo. The rate-limiting step in the classical bile acid
synthesis pathway utilizes the liver-specific enzyme Cyp7A1,
which converts cholesterol into 7-hydroxycholesterol (39, 41,
56). The down-regulation of this gene (Fig. 6) should lead to
more accumulation of cholesterol concomitant with less con-
version of hepatic cholesterol to bile acids in DN2-TG mice.
The impaired expression of SREBP-1c (Fig. 6), a transcription
factor that regulates the expression of various lipogenic genes,
including those encoding acetyl-CoA carboxylase and fatty acid
synthase (15), is likely responsible for the decreased de novo
lipogenesis in the liver (Fig. 4). The down-regulation of
ABCG5 (3, 38), encoding an ABC transporter implicated in
biliary cholesterol excretion, may also lead to the observed
cholesterol accumulation in the livers of DN2-TG mice. These
results are correlated with the observed phenotypes of
DN2-TG mice with regard to dietary-cholesterol-mediated
regulation of hepatic and plasma cholesterol levels (Fig. 3D
and E), as well as T0901317-mediated regulation of hepatic
trigylceride levels (Fig. 4B). However, we observed at least two
lines of data inconsistent with the previous reports about the
regulatory function of LXRs in lipid metabolism. Hepatic tri-
glyceride levels were significantly increased in DN2-TG mice
fed high-cholesterol diets, unlike LXR/ mice (35). In ad-
dition, plasma triglyceride levels were significantly increased
with T0901317-treated DN2-TG mice, while LXR/ double-
knockout mice had only a slight increase (41). A few possibil-
ities exist. First, DN2 may bind still other uncharacterized
nuclear receptors, and the impairment of the signaling pathway
for these receptors may lead to the observed triglyceride phe-
notypes. Consistent with this possibility, many genes that are
not responsive to T0901317 in wild-type mice were altered in
expression in DN2-TG mice (AA238618, W36002, AA472154,
and AA177717 [Table 4], for instance). We are currently in-
vestigating whether DN2 binds to other receptors, particularly
those known to be involved with lipid metabolism, such as
PPAR (1), PXR (10), ROR (52), and Rev-erbA (6). One
likely group of physiological target genes of these putative
non-LXR-type receptors that lead to the altered triglyceride
levels may involve genes regulating triglyceride clearance. In
this regard, it was interesting that the gene for very low density
lipoprotein receptor (45), which was not significantly regulated
by T0901317 in wild-type mice, was identified as a gene tar-
geted by DN2 in DN2-TG mice. Secondly, it should be noted
that DN2-TG mice are clearly different from LXR/ double-
knockout mice. In the former mice, the functional endogenous
ASC-2 still exists, so LXR signaling can function at least to
some extent, while LXR signaling should be completely off in
the latter mice. In particular, in the presence of higher doses of
T0901317, a subset of LXR target genes were significantly
up-regulated in DN2-TG mice, likely through the ability of this
potent synthetic LXR ligand to overcome the repressive effect
of DN2 (data not shown).
Our cDNA microarray experiments suggested a number of
novel roles of LXRs and ASC-2 in the murine liver (Tables 2
through 4). It was noted that many genes previously described
as constitutive androstane receptor (CAR) and/or PPAR tar-
get genes, including those encoding Cyp4A10, Cyp4A14, and
Cyp3A11 (2, 49), were modulated by T0901317 in wild-type
mice, suggesting a novel cross talk between LXRs and CAR/
PPAR signaling pathways. The gene for angiogenin-3, a po-
tent activator of angiogenesis (11), emerged as a down-regu-
lated target gene of ASC-2 and T0901317. Consistent with
these results, our preliminary results indicated that T0901317
exhibits antiangiogenic effects with cultured human umbilical
vein endothelial cells. As shown in Fig. 5C, T0901317 also
showed a complex regulation of different IB kinases. Since
various NF-B-activating signals may differentially utilize dif-
ferent IB kinases (36), these results suggest a novel regulatory
role of LXRs in NF-B transactivation. It was also surprising
to observe the up-regulation of PPAR by T0901317 (Fig. 5A).
Consistent with the previous work implicating PPAR in the
regulation of CD36 expression and macrophage uptake of ox-
idized LDL (7), CD36 also turned up as a T090317-induced
gene in our microarray assays (Tables 2 and 3). It was recently
shown that PPAR induces ABCA1 expression and cholesterol
removal from macrophages through a transcriptional cascade
mediated by the nuclear receptor LXR (8). Thus, these re-
sults suggest a possible autoregulatory loop between PPAR
and LXRs present in the murine liver. Finally, it was intriguing
that insig-2 was up-regulated by not only T0901317 (Tables 2
and 3 and Fig. 5) but also agonists of other metabolically
FIG. 6. RT-PCR analyses of LXR target genes in DN2-TG mice.
Total RNA was prepared from wild-type (WT) and DN2-TG (TG)
mice untreated or treated with either a high-cholesterol diet for 60
days (A) or 50 mg of T0901317/kg for 6 days (B). Semiquantitative
RT-PCR was used to determine the relative levels of mRNA for
lipoprotein lipase (LPL), ABCA1, ABCG1, ABCG5, ABCG8,
SREBP-1c, fatty acid synthase (FAS), Cyp7A1, LXR, SCD-1, acetyl-
CoA carboxylase (ACC), DN2, GAPDH, and -actin.
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important receptors, such as PPAR, PPAR, and vitamin D
receptor (our unpublished results). These results implicate in-
sig-2 as a central sensor protein for various cellular conditions
that call for a shutdown of cholesterol-lipid synthesis in vivo.
Notably, our cDNA microarray experiments identified many
additional genes that may unravel yet other exciting and un-
expected functions of LXRs and ASC-2.
Recently, LXRs were shown to be endogenous inhibitors of
atherogenesis (22). We found that DN2 was also expressed in
macrophages of DN2-TG mice. Thus, bone marrow transplan-
tations were exploited to assess the effect of selectively elimi-
nating the LXR function of macrophages (i.e., bone marrow
transplantation of macrophages from DN2-TG mice into mu-
rine models of atherosclerosis). These mice with transplants
mimicked many aspects of Tangier disease, a human high-
density lipoprotein deficiency, including aberrant regulation of
cholesterol transporter expression (i.e., ABCA1 and ABCG1),
lipid accumulation in macrophages, and increased atheroscle-
rosis (our unpublished results). These results, along with the
results presented in this report, strongly suggest that ASC-2 is
a bona fide coactivator of LXRs in vivo.
In conclusion, we established novel transgenic mouse lines
expressing a dominant-negative fragment of ASC-2 that spe-
cifically blocks the recruitment of endogenous ASC-2 to LXRs
bound to the target promoters. We demonstrated that these
mice were indeed impaired in the ability to respond to dietary
cholesterol and the synthetic LXR ligand T0901317. These
results, along with the recent results with DN1-TG mice (18),
led us to conclude that ASC-2 is a physiologically important
transcriptional coactivator of LXRs and other nuclear recep-
tors in vivo. From the livers of these mice, we further isolated
a series of novel genes that are targeted by ASC-2 and
T0901317. Studies of these genes will provide further insights
into the molecular mechanisms for the roles of ASC-2 with
regard to LXRs in dietary-cholesterol metabolism and lipogen-
esis in the liver.
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